Oncolytics Biotech (ONCY) Other Operating Expenses (2009 - 2022)

Oncolytics Biotech (ONCY) has reported Other Operating Expenses for 14 consecutive years, with -$2.5 million the latest figure, recorded in Q2 2022.

• In Q2 2022, Other Operating Expenses fell 1071.95% year-over-year to -$2.5 million; the TTM figure through Mar 2023 stood at -$2.5 million (up 69.33% YoY), while the FY2022 annual figure was -$11.9 million, down 15.13% from the prior year.
• Other Operating Expenses rose to -$2.5 million in Q2 2022 per ONCY's latest filing, from -$2.9 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $396261.2 in Q2 2020 and bottomed at -$2.9 million in Q1 2022.
• Historically, Other Operating Expenses has averaged -$967534.6 across 5 years, with a median of -$753102.8 in 2018.
• Annual changes were most pronounced in 2019 — Other Operating Expenses surged 137.79% — and 2021, when it sank 7280.63%.
• Oncolytics Biotech's Other Operating Expenses stood at -$461143.0 in 2018, then soared by 137.79% to $174277.0 in 2019, then slumped by 122.69% to -$39546.3 in 2020, then tumbled by 7280.63% to -$2.9 million in 2021, then gained by 13.91% to -$2.5 million in 2022.
• Business Quant data shows ONCY's Other Operating Expenses at -$2.5 million in Q2 2022, -$2.9 million in Q1 2022, and -$2.9 million in Q4 2021.